Adding methotrexate for blood cancers not controlled by current therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial is testing whether adding a low dose of methotrexate (a medicine often used for arthritis) can help people with certain blood cancers (myelofibrosis, polycythemia vera, or essential thrombocythemia) whose current treatments are not controlling their symptoms or blood counts well enough.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a confirmed diagnosis of one of these blood cancers: polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (MF), or MF that started from PV or ET
- You've been on a stable dose of your current treatment for at least 12 weeks, but you still have symptoms (like fatigue, itching, or spleen discomfort) or abnormal blood counts (high white blood cells, high platelets, or needing regular phlebotomies)
- Your organs are working well enough (liver, kidneys, and blood cell counts are within safe limits)
- You do not have serious heart, lung, liver, or infection problems, and you have not taken methotrexate before for another condition
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called PRT12396 for people with myeloproliferative neoplasms (MPN). It aims to see if the drug is safe and helps control the disease.
This trial tests an oral drug combination for people with advanced myeloproliferative neoplasms (MPNs), which are blood cancers. The treatment may help control the disease and improve symptoms.
This trial tests whether adding a medication that helps the body make more platelets (called rhTPO) to the usual treatment (cyclosporine) can improve platelet counts and reduce bleeding in people with a type of bone marrow disorder called lower-risk MDS. It may help those who have very low platelets and are at risk of bleeding.
This trial tests two new medicines, selinexor and pacritinib, for people with myelofibrosis who have low blood counts and have not yet tried JAK inhibitor therapy. The goal is to see if this combination helps reduce spleen size and improve blood counts.
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
This Phase 2 trial tests whether giving high-dose methotrexate into the bloodstream can help treat breast cancer that has spread to the thin lining covering the brain and spinal cord. It may help reduce cancer in the leptomeningeal (brain-lining) area and control symptoms.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.